Bisphosphonate treatment in osteogenesis imperfecta: Which drug, for whom, for how long?

Annals of Medicine

Volumn 37, Issue 4, 2005, Pages 295-302

  Rauch, Frank ^a   Glorieux, Francis H ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

Bisphosphonate; Children; Collagen; Osteogenesis imperfecta; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BODY MOVEMENT; BONE DEFECT; BONE DEFORMATION; BONE FRAGILITY; BONE GROWTH; BONE MASS; BONE PAIN; BONE REMODELING; CHILD GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FETUS RISK; FRACTURE; FRACTURE HEALING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; LONG TERM CARE; METAPHYSIS; OSTEOGENESIS IMPERFECTA; PES EQUINOVARUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TERATOGENICITY; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VERTEBRA FRACTURE; WOUND HEALING IMPAIRMENT;

DECISION MAKING; DIPHOSPHONATES; HUMANS; OSTEOGENESIS IMPERFECTA; TREATMENT OUTCOME;

EID: 21344452794     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890510007386     Document Type: Review

References (46)

1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377-85.
2. Shapiro JR, Stover ML, Burn VE, McKinstry MB, Burshell AL, Chipman SD, et al. An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro alpha 1(I) chain of type I collagen. J Clin Invest. 1992;89:567-73.
3. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-16.
4. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002;17:30-8.
5. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000;15: 1650-8.
6. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 2002;31: 12-8.
7. Engelbert RH, Pruijs HE, Beemer FA, Helders PJ. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil. 1998;79:1590-4.
8. Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B. 2003;12:77-87.
9. Engelbert RH, Beemer FA, van der Graaf Y, Helders PJ. Osteogenesis imperfecta in childhood: impairment and disability-a follow-up study. Arch Phys Med Rehabil. 1999;80:896-903.
10. Gerber LH, Binder H, Berry R, Siegel KL, Kim H, Weintrob J, et al. Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Arch Phys Med Rehabil. 1998;79:46-51.
11. Wilkinson JM, Scott BW, Clarke AM, Bell MJ. Surgical stabilisation of the lower limb in osteogenesis imperfecta using the Sheffield Telescopic Intramedullary Rod System. J Bone Joint Surg Br. 1998;80:999-1004.
12. Karbowski A, Schwitalle M, Brenner R, Lehmann H, Pontz B, Worsdorfer O. Experience with Bailey-Dubow rodding in children with osteogenesis imperfecta. Eur J Pediatr Surg. 2000;10:119-24.
13. Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 2001;29:553-9.
14. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100.
15. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16:360-3.
16. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339:947-52.
17. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86:356-64.
18. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846-50.
19. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta-lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab. 2002;15: 163-74.
20. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18:610-4.
21. Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone. 2004;34: 539-46.
22. Sumnik Z, Land C, Rieger-Wettengl G, Korber F, Stabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res. 2004;61: 137-42.
23. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110:1293-9.
24. Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone. 2003;32:268-74.
25. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during long-term therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV. Pediatrics. 2003;111:1030-6.
26. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18:126-30.
27. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-61.
28. Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr. 2003;92:452-5.
29. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363: 1427-31.
30. Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol. 2003;33:226-9.
31. Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res. 2004;19: 1191-3.
32. Leonard MB. Assessment of bone health in children and adolescents with cancer: promises and pitfalls of current techniques. Med Pediatr Oncol. 2003;41:198-207.
33. Fewtrell MS. Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child. 2003;88:795-8.
34. Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int. 2003:103-12.
35. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996;11:150-9.
36. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003;88:986-92.
37. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349:457-63.
38. Bikle DD, Morey-Holton ER, Doty SB, Currier PA, Tanner SJ, Halloran BP. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J Bone Miner Res. 1994;9:1777-87.
39. Roschger P, Grabner BM, Rinnerthaler S, Tesch W, Kneissel M, Berzlanovich A, et al. Structural development of the mineralized tissue in the human L4 vertebral body. J Struct Biol. 2001;136:126-36.
40. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779-86.
41. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12:1700-7.
42. Munns CF, Rauch F, Ward L, Glorieux FH. Effect of prenatal pamidronate therapy on maternal and fetal outcome: A report of two cases. J Bone Miner Res. 2004;19:1742-5.
43. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr. 2001;160:641-4.
44. Banerjee I, Shortland GJ, Evans WD, Gregory JW. Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child. 2002;87:562-3.
45. Giraud F, Meunier PJ. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint Bone Spine. 2002;69:486-90.
46. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics. 2003;111: 573-8.